GHP Q3 2021

10 GHP / Q3 2021 , Feb21449 DCISionRT is the culmination of ground-breaking technology created by PreludeDx, the California-based breast cancer diagnostics company dedicated to improving treatment and care for patients. Using advanced artificial intelligence andmachine learning, DCISionRT provides personalized results that influence physician decisions regarding the best treatment pathway for individual patients diagnosed with ductal carcinoma in situ (DCIS), also known as Stage 0 breast cancer, enablingmore effective care and alleviating guesswork on healthcare providers when rendering treatment recommendations. Find out more about the science behind DCISionRT and the team leading a revolution in cancer treatment. Personalizing Decision-Making for Breast Cancer Treatment Founded in 2006, PreludeDx is a leading personalized breast cancer diagnostics company in the US. The company’s mission is to provide physicians with the tools for better decision-making concerning patient treatment and care. Old testing methods that use clinical and pathological factors are getting an upgrade, now incorporating genomic testing through advanced AI technology that enables accuracy and personalization. In doing so, PreludeDx aims to improve the outcomes of patients afflicted with breast cancer, while simultaneously alleviating financial burdens and pressures on resources within healthcare systems. The Science Behind the Innovation Using technology licensed from the University of California, San Francisco, PreludeDx created actionable, evidence-based tools in the form of a patented molecular test. DCISionRT is currently the only DCIS (ductal carcinoma in situ) test designed to predict radiation therapy benefit. The test combines cutting-edge innovation in molecular biology with AI and machine learning to analyze the tumors of women diagnosed with DCIS breast cancer. Relying on a comprehensive assessment of the proven disease progression pathways along with standard clinical factors, the test is able to predict the individualized likelihood of these women developing a DCIS recurrence and/or invasive breast cancer within ten years, with and without adjuvant radiation therapy after Breast Conserving Surgery (BCS). DCIS is currently the most commonly diagnosed form of non-invasive breast cancer, affecting more than 60,000 women in the US alone each year. And while there are a variety of treatment patterns available for DCIS that utilize clinicopathological features and nomograms, none share the same personalization and quantification of risk and radiation therapy benefit as DCISionRT. This defaults to a one-size-fitsall approach in which many patients receive radiation therapy regardless of their unique level of risk, creating a prevalence of both over- and under-treatment. The research to create DCISionRT was built on funding from the National Cancer Institute in an effort to better understand the biology of DCIS. In the largest combined study population ever carried out in the development Best DCIS Testing Solution 2021: DCISionRT®